Not yet a member?

    Popular Topics
    Search


    Forums
  • Forums
  • Ask a question about:

  • Archived Onctalk Forums
    Our Supporters
    Syndication
    Subscribe

Podcast of Q&A Portion from Molecular Markers Webinar with Dr. Pennell

March 7, 2010 - 12:52 pm

   Here’s the podcast of the Q&A portion of the excellent webinar with Dr. Pennell on Molecular Markers in Management of NSCLC
dr-pennell-molecular-markers-qa-audio-podcast
dr-pennell-molecular-markers-qa-transcript
dr-pennell-molecular-markers-qa-figures

0 Comments

Loading the Dice: Comparative Trials of EGFR Inhibitors in Patients with EGFR Mutations (or, When Bad Trials Happen to Good People)

February 19, 2010 - 10:30 pm

The IPASS trial that randomized Asian never-smoking or light previously smoking patients with previously untreated advanced NSCLC to either standard chemo or the epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI)  inhibitor Iressa (gefitinib) is widely considered among the most important and standard-changing trials of the last few years in the field of lung [...]

14 Comments

Molecular Markers from the INTEREST Trial: Chemo and EGFR Inhibitor Therapy Still Remarkably Equivalent

February 13, 2010 - 3:08 pm

Oncologists often have their own ideas about how effective or ineffective a targeted therapy like an EGFR tyrosine kinase inhibitor (TKI) (Tarceva (erlotinib) or Iressa (gefitinib)) is compared with standard chemotherapy options.   We’ve seen a lot of new information emerge in the field over the last few years, and we now have evidence that [...]

6 Comments

Dr. Pennell on Emerging Molecular Markers in NSCLC Management: Podcast Now Available

February 3, 2010 - 2:01 pm

   We know that many people interested in the topics we discuss in our webinars may not be able to attend the live programs, but we’re committed to offering our content to people as easily as possible.   Accordingly, here is the podcast version of Dr. Pennell’s very well received presentation on a range of molecular [...]

0 Comments

Round Table Case-Based Discussion — Drs. Laskin and Sandler on First Line and Maintenance Chemo

January 14, 2010 - 2:11 pm

  This is a continuation of the round table format, discussing real life case management with my colleagues who are lung cancer experts at other institutions,  This case is the second half of discussion centered around a never-smoking Asian woman who doesn’t have an EGFR mutation, and specifically the decision-making process of what first line chemotherapy-based treatment to [...]

2 Comments

Webinar on “Molecular Markers in Lung Cancer”: Join us on Jan 20th

January 7, 2010 - 10:10 pm

As one more way to reach patients and caregivers everywhere, we’re going to do our first live “webinar” (as in, web-based seminar) in two weeks.  Our own beloved Dr. Nathan Pennell, of Cleveland Clinic and GRACE faculty fame, will present a talk with slides on “The Evolving Role of Molecular Markers in Managing Non-Small Cell [...]

2 Comments

Round Table Case-Based Discussion — Drs. Laskin and Sandler on Molecular Testing in a Never-Smoker

January 6, 2010 - 6:37 pm

Here is the first podcast of what we plan will be an ongoing series of round table discussions with cancer experts about real case scenarios and how we make decisions in practice.  My guests for the discussion are Drs. Janessa Laskin, medical oncologist from British Columbia Cancer Agency in Vancouver, BC, and Alan Sandler, medical [...]

1 Comments

What I really do: Molecular testing for NSCLC

December 31, 2009 - 8:58 am

I’m fortunate to practice at Moffitt, where Dr. Gerold Bepler and Dr. George Simon pioneered a molecularly directed approach to front-line chemotherapy in NSCLC. Data from the phase II clinical trial demonstrated impressive median survival for a platinum-based doublet: 13.3 months. The schema of the MADeIT clinical trial is shown below and I’m happy to [...]

5 Comments

Evidence of the Impact of Environmental Tobacco Smoke in Never-Smokers: Correlations with EGFR Mutations

December 26, 2009 - 6:04 am

It seems obvious: environmental tobacco smoke (ETS)/passive smoke exposure from being around smokers, can be harmful and may cause cancer in never-smokers.  A new paper in the Journal of Clinical Oncology by Lee and colleagues from Korea actually offers some evidence that highlights this, showing that never-smokers in Korea were less likely to have an [...]

6 Comments

Dr. George Simon on Individualizing Treatment Recommendations in Advanced NSCLC using Molecular Factors

December 20, 2009 - 7:27 am

Dr. George Simon, medical oncologist and Director of the Thoracic Oncology Program at Fox Chase Cancer Center in Philadelphia, has been kind enough to sit down for an interview with me earlier this year, which was made into a podcast several months ago.  More recently, he participated in our NSCLC Patient Education, sponsored by OSI [...]

0 Comments
« Previous Entries